Today, biopharmaceutical company MapLight Therapeutics announced encouraging results from a Phase 2 trial testing a new investigational treatment for schizophrenia. The medication met its main goal, showing a statistically significant and clinically meaningful improvement in psychiatric symptoms compared to placebo — along with an early, promising signal on cognitive function, an area that's historically been hard to treat. It's good news. And it's a reminder of something we
Some memory changes are a normal part of aging. However, certain changes are not considered normal and should be evaluated by a healthcare professional. Understanding the difference can help you or a loved one seek help early, when treatments and planning can be most effective.
